Document Detail

Continuous flow left ventricular assist device outcomes in commercial use compared with the prior clinical trial.
MedLine Citation:
PMID:  21958789     Owner:  NLM     Status:  In-Data-Review    
BACKGROUND: A multicenter clinical trial conducted from 2005 to 2008 of a continuous flow left ventricular assist device (LVAD) resulted in Food and Drug Administration approval for bridge to transplantation. The purpose of this analysis was to determine changes in posttrial outcomes in widespread commercial use since the clinical trial.
METHODS: We compared outcomes of 486 patients who received a continuous flow LVAD as a bridge to transplantation at 36 centers during the clinical trial (March 2005 to April 2008) with outcomes of 1,496 posttrial patients who received a continuous flow LVAD at 83 centers (April 2008 to September 2010 as reported to the Interagency Registry for Mechanically Assisted Circulatory Support).
RESULTS: Baseline data were comparable between groups. Cumulative follow-up was 511 and 1,082 patient-years for trial and posttrial patients, respectively, and average support duration was 12.6 ± 14.0 and 8.7 ± 7.1 months. Kaplan-Meier survival improved at 1 year from 76% (trial) to 85% (posttrial). The percentage of patients undergoing transplantation in the first year decreased from 48% in the trial period to 39% in the posttrial period. Quality of life metrics improved by 3 months in both groups.
CONCLUSIONS: The survival rate of a large group of continuous flow LVAD patients in a real-world setting after Food and Drug Administration market approval for bridge to transplantation has improved since the clinical trial. These data show that excellent outcomes have been maintained with dissemination of new LVAD technology from a clinical trial phase to more broad based use in the period after market approval.
Ranjit John; Yoshifumi Naka; Nicholas G Smedira; Randall Starling; Ulrich Jorde; Peter Eckman; David J Farrar; Francis D Pagani
Related Documents :
21736509 - Long-term carriage of extended-spectrum beta-lactamase-producing escherichia coli.
21792049 - Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calc...
8730249 - Triple therapy with sucralfate, amoxycillin and metronidazole for healing duodenal ulce...
22008059 - Low-intensity extracorporeal shock wave therapy--a novel effective treatment for erecti...
25219699 - An european multicenter randomized noninferiority trial comparing 180-w greenlight-xps ...
21801329 - Efficacy and safety of bronchoscopic laser therapy in patients with tracheal and bronch...
15168179 - Wear of ultra-high-molecular-weight polyethylene cup articulating with 22.225 mm zircon...
1860289 - Malarial chemoprophylaxis and the healing of periodontal lesions.
19057249 - Clinical outcome of nonoperative treatment for lumbar spinal stenosis, and predictive f...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The Annals of thoracic surgery     Volume:  92     ISSN:  1552-6259     ISO Abbreviation:  Ann. Thorac. Surg.     Publication Date:  2011 Oct 
Date Detail:
Created Date:  2011-09-30     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  15030100R     Medline TA:  Ann Thorac Surg     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  1406-13     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2011 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
Cardiothoracic Surgery, University of Minnesota, Minneapolis, Minnesota.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Left atrial ablation versus biatrial ablation in the surgical treatment of atrial fibrillation.
Next Document:  Clinical impact of concomitant tricuspid valve procedures during left ventricular assist device impl...